, the UK-based clinical AI technology company, announced on Wednesday that it had inked a two-year agreement with global pharmaceutical firm Bayer to develop new treatments targeting cardiovascular disease.
The deal is expected to generate revenues of £5 million across the two years, with NHS trusts, a partner of Sensyne, to receive a 4% share of revenues from the collaboration.
The two companies will work together utilising Sensyne’s AI technology platform to accelerate clinical developments for new treatments targeting cardiovascular disease, a condition the NHS identified as a “clinical priority” in its Long Term Plan published at the start of 2019.
One core focus cited within the NHS’s plan is to improve outcomes across major diseases and the collaboration clearly supports this goal -- heart disease is reported to affect around 7 million people in the UK alone, accounting for one in four premature deaths.
Lord Paul Drayson, CEO of Sensyne Health, commented: "We are delighted to announce this new agreement with Bayer, which aims to accelerate the clinical development of new treatments for cardiovascular disease, a clinical priority for the NHS, using Sensyne Health's proprietary clinical AI technology platform."
Shares perked up almost 7% following this morning’s news.
The collaboration also marks a significant move to address an area which has received little investment over the last twenty years, the company explained, and it seems the use of artficial intelligence to address an area that has seen little innovation will be a valuable asset in driving forward drug discovery here.
Alongside this, real world evidence collected from Sensyne’s AI analysis of anonymised patient data corroborates the credibility of the platform to drive forward patient outcomes and drug discovery.
Additionally, Sensyne has underlined that they are working within a “ethical framework and business model”, with the NHS remaining the sole controller of patient data, eliminating the sale or transfer of data to a third party. The company will act as a ‘docking station’ for the analysis of anonymised patient data on behalf of commercial partners under strict ethical control.
For more News and Updates on Sensyne Health:
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.
The group said it will apply for a liquefied natural gas ("LNG") import licence for Ireland and has reached a number of confidentiality agreements with a global supplier of LNG and and an owner of LNG regasification vessels.
British car manufacturing came to a screeching halt in April, down 99.7% against the same month last year. It was the lowest output since the Second World War with just 197 premium and luxury sports vehicles rolled off factory lines, with 45 of those sent to UK customers.
The group has released its final results for the period ending 31 December 2019 and has highlighted the surge in revenue as largely driven by a £8.6m or 34% contribution from environmental services firm, Watbio, which the company snapped up in December 2018.